Revolution Medicines CEO Sells Over $1.5M in Stock

On June 16, 2026, Mark Goldsmith, the President and CEO of Revolution Medicines, Inc. (NasdaqGS:RVMD), sold 10,020 shares of the company. The shares were sold at an average price of $156.12, totaling approximately $1.56 million. This transaction was part of a planned sale under Rule 10b5-1.

Insider Buying and Selling at Revolution Medicines, Inc.

Several insiders at Revolution Medicines also made stock transactions on June 16, 2026. Kelsey Stephen Michael, President of Research and Development, sold 4,175 shares, while General Counsel Jeff Cislini sold 2,157 shares. CFO Jack Anders sold 2,722 shares, and Chief Global Commercialization Officer Anthony Mancini sold 4,615 shares. Each transaction was conducted at an average price of $156.12 per share and was planned under Rule 10b5-1, except for Mancini's sale.

Other Institutional Activity in Revolution Medicines

Institutional investors have been active with Revolution Medicines' stock. BlackRock, Inc. increased its holdings by 2,286,050 shares, ending with 11,212,706 shares valued at approximately $1.09 billion. On the other hand, Janus Henderson Group PLC reduced its stake by 2,537,006 shares, now holding 9,766,496 shares worth about $949.54 million. Farallon Capital Management LLC trimmed its position by 978,000 shares, leaving it with 13,604,796 shares valued at around $1.32 billion.

Revolution Medicines, Inc. Stock Down 24.1%

Shares of Revolution Medicines are trading near $157.77. The company has a market cap of approximately $33.54 billion. Though it is not currently profitable, it has a forward P/E ratio of -27.66 and a beta of 1.407, indicating some volatility. The stock's 52-week range is between $34.00 and $166.50, with moving averages of $145.17 over 50 days and $94.56 over 200 days. Revolution Medicines maintains a strong liquidity position with a current ratio of 6.795.

Analysts Set New Price Targets

Analyst firms have maintained a positive outlook on Revolution Medicines. On June 10, 2026, Evercore ISI Group maintained a 'buy' rating with a price target of $220. RBC Capital also kept its 'buy' rating, setting a target of $182 on June 2, 2026. The consensus among 21 analysts is a 'strong buy', with a mean price target of $187.29.

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage biotechnology company based in Redwood City, California. It focuses on developing targeted therapies for RAS-addicted cancers. The company's pipeline includes RAS(ON) inhibitors like daraxonrasib and elironrasib G12C, aimed at treating solid tumors and other cancer types. Revolution Medicines was founded in 2014 and is led by CEO Dr. Mark A. Goldsmith.

Bottom Line

The recent insider sales, including CEO Mark Goldsmith's, were planned transactions and part of routine stock management. Revolution Medicines continues to attract institutional interest, with varied positions among major funds. Analyst sentiment remains bullish, reflecting confidence in the company's future prospects. As with all 13F and insider filings, these actions may not represent current positions, serving primarily as historical data for investors.